Montelukast (montelukast): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Montelukast 10 mg film coated tablets

Montelukast 10 mg film-coated tablets is indicated in the treatment of asthma as add-on therapy in adults and adolescents from 15 years of age and older with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting beta-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montelukast 10 mg film-coated tablets is indicated in asthma, Montelukast 10 mg film-coated tablets can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast 10 mg film-coated tablets is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 10 mg Film Coated Tablets

Montelukast film-coated tablet is indicated in the treatment of asthma as add-on therapy in adults and adolescents from 15 years of age and older with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom as-needed short acting β-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montelukast film-coated tablet is indicated in asthma, Montelukast Film-coated tablet can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast Film-coated tablet is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 10 mg film-coated tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in adolescents and adults from 15 years of age with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting beta-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom Montelukast is indicated in asthma, Montelukast can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 10mg Film-coated Tablets

Montelukast 10mg Film-coated Tablets are indicated in the treatment of asthma as add-on therapy in those patients 15 years of age and older with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom as-needed short acting β-agonists provide inadequate clinical control of asthma. In those asthmatic patients 15 years of age and older in whom Montelukast 10mg Film-coated Tablets are indicated in asthma, Montelukast 10mg Film-coated Tablets can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast 10mg Film-coated Tablets are also indicated in the prophylaxis of asthma in patients 15 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 4 mg chewable Tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short acting β-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 4 mg chewable tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old children with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short-acting beta-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old children with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids

Montelukast is also indicated in the prophylaxis of asthma from 2 years of age and older children in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 4mg chewable Tablets

Montelukast 4mg chewable Tablets is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom as-needed short acting β-agonists provide inadequate clinical control of asthma.

Montelukast 4mg chewable Tablets may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast 4mg chewable Tablets is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 4mg Chewable Tablets

Montelukast is indicated in paediatric patients aged 2 to 5years in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short-acting beta-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to5years old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids

Montelukast is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 5 mg chewable Tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in those 6 to 14 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short acting β-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 5 mg chewable tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in those 6 to 14 year old children with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short-acting beta-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 year old children with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids

Montelukast is also indicated in the prophylaxis of asthma from 6 years of age and older children in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 5 mg Chewable Tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in those 6 to 14 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short-acting beta-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast is also indicated in the prophylaxis of asthma for 6 to 14 year old patients in which the predominant component is exerciseinduced bronchoconstriction.

Montelukast 5mg chewable Tablets

Montelukast 5mg chewable Tablets is indicated in the treatment of asthma as add-on therapy in those 6 to 14 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom as-needed short acting β-agonists provide inadequate clinical control of asthma.

Montelukast 5mg chewable Tablets may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast 5mg chewable Tablets is also indicated in the prophylaxis of asthma in 6 to 14 year old patients in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 5mg Chewable Tablets

Montelukastis indicated in paediatric patients aged 6 to 14 years in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short-acting beta-agonists provide inadequate clinical control of asthma.

Montelukastmay also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 years old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids

Montelukastis also indicated in the prophylaxis of asthma from6 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Montelukast paediatric 4 mg chewable tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short-acting β-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Montelukast paediatric 5 mg chewable tablets

Montelukast is indicated in the treatment of asthma as add-on therapy in those 6 to 14 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short-acting β-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

Montelukast Sodium 4 mg Oral Granules

Montelukast is indicated in the treatment of asthma as add-on therapy in those 6 months to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom as-needed short acting beta-agonists provide inadequate clinical control of asthma.

Montelukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

Montelukast is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.
Route of administration: Oral
Molecule: montelukast

Patients' opinions on Montelukast

In brief

General satisfaction level: 8.00/10 Learn more

Treatment's effectiveness: 8.50/10 Learn more

Ease of use: 9.50/10 Learn more

Adherence to prescription: 10.00/10 Learn more

Detected side effects: Be the first to evaluate

Improvement in the quality of life: 9.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
Cluggy
on 08/04/2021

Miss one dose and sinus infection 

Your message

Members using this Montelukast

Conditions related to this medication

Fact sheet

Asthma

See the fact sheet